Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T cell immunity to tumor antigens

Personalized cancer vaccines (PCVs) targeting patient-specific neoantigens are a promising cancer treatment modality; however, neoantigen physicochemical variability can present challenges to manufacturing PCVs in an optimal format for inducing anticancer T cells. Here, we developed a vaccine platfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynn, Geoffrey M., Sedlik, Christine, Baharom, Faezzah, Zhu, Yaling, Ramirez-Valdez, Ramiro A., Coble, Vincent L., Tobin, Kennedy, Nichols, Sarah R., Itzkowitz, Yaakov, Zaidi, Neeha, Gammon, Joshua M., Blobel, Nicolas J., Denizeau, Jordan, de la Rochere, Philippe, Francica, Brian J., Decker, Brennan, Maciejewski, Mateusz, Cheung, Justin, Yamane, Hidehiro, Smelkinson, Margery G., Francica, Joseph R., Laga, Richard, Bernstock, Joshua D., Seymour, Leonard W., Drake, Charles G., Jewell, Christopher M., Lantz, Olivier, Piaggio, Eliane, Ishizuka, Andrew S., Seder, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065950/
https://www.ncbi.nlm.nih.gov/pubmed/31932728
http://dx.doi.org/10.1038/s41587-019-0390-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065950/
https://www.ncbi.nlm.nih.gov/pubmed/31932728
http://dx.doi.org/10.1038/s41587-019-0390-x

Ejemplares similares